Evaluation of the Febrile Patient in the ICU

  • Alexis Tabah
  • François Philippart
  • Jean Carlet


Normal body temperature is generally considered to be 36.8°C (98.2°F), with 37.7°C (99.9°F) as an upper limit in healthy adults.1 A wide range of biologic processes, some infectious and many noninfectious, can cause temperature elevation. Some of the noninfectious conditions can be as life-threatening as infectious ones.2


Intensive Care Unit Patient Invasive Candidiasis Mesenteric Ischemia Acalculous Cholecystitis Postoperative Fever 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA. 1992;268(12):1578–1580.PubMedGoogle Scholar
  2. 2.
    O’Grady NP, Barie PS, Bartlett J, et al. Practice parameters for evaluating new fever in critically ill adult patients. Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. Crit Care Med. 1998;26(2):392–408.PubMedGoogle Scholar
  3. 3.
    Mackowiak PA. Concepts of fever. Arch Intern Med. 1998;158(17):1870–1881.PubMedGoogle Scholar
  4. 4.
    Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596.PubMedGoogle Scholar
  5. 5.
    Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31(12):2742–2751.PubMedGoogle Scholar
  6. 6.
    Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462–474.PubMedGoogle Scholar
  7. 7.
    Valles J, Rello J, Ochagavia A, et al. Community-acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123(5):1615–1624.PubMedGoogle Scholar
  8. 8.
    Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33(7):1538–1548.PubMedGoogle Scholar
  9. 9.
    Jimenez MF, Marshall JC. Source control in the management of sepsis. Intensive Care Med. 2001;27(Suppl 1):S49–S62.PubMedGoogle Scholar
  10. 10.
    Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis. 2004;17(4):309–316.PubMedGoogle Scholar
  11. 11.
    Aarts MA, Brun-Buisson C, Cook DJ, et al. Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome? Intensive Care Med. 2007;33(8):1369–1378.PubMedGoogle Scholar
  12. 12.
    Misset B, De Jonghe B, Bastuji-Garin S, et al. Mortality of patients with heatstroke admitted to intensive care units during the 2003 heat wave in France: a national multiple-center risk-factor study. Crit Care Med. 2006;34(4):1087–1092.PubMedGoogle Scholar
  13. 13.
    Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.PubMedGoogle Scholar
  14. 14.
    Blatteis CM. Endotoxic fever: new concepts of its regulation suggest new approaches to its management. Pharmacol Ther. 2006;111(1):194–223.PubMedGoogle Scholar
  15. 15.
    Saper CB, Breder CD. The neurologic basis of fever. N Engl J Med. 1994;330(26):1880–1886.PubMedGoogle Scholar
  16. 16.
    Mackowiak PA, Boulant JA. Fever’s glass ceiling. Clin Infect Dis. 1996;22(3):525–536.PubMedGoogle Scholar
  17. 17.
    Blatteis CM, Sehic E, Li S. Pyrogen sensing and signaling: old views and new concepts. Clin Infect Dis. 2000;31(Suppl 5):S168–S177.PubMedGoogle Scholar
  18. 18.
    Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol. 1985;134(6):3868–3875.PubMedGoogle Scholar
  19. 19.
    Mickenberg ID, Snyderman R, Root RK, et al. The relationship of complement consumption to immune fever. J Immunol. 1971;107(5):1466–1476.PubMedGoogle Scholar
  20. 20.
    Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328(2):106–113.PubMedGoogle Scholar
  21. 21.
    Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med. 1994;45:491–503.PubMedGoogle Scholar
  22. 22.
    Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986;163(6):1433–1450.PubMedGoogle Scholar
  23. 23.
    Dinarello CA, Bernheim HA, Duff GW, et al. Mechanisms of fever induced by recombinant human interferon. J Clin Invest. 1984;74(3):906–913.PubMedGoogle Scholar
  24. 24.
    Blatteis CM, Bealer SL, Hunter WS, et al. Suppression of fever after lesions of the anteroventral third ventricle in guinea pigs. Brain Res Bull. 1983;11(5):519–526.PubMedGoogle Scholar
  25. 25.
    Blatteis CM, Hales JR, McKinley MJ, et al. Role of the anteroventral third ventricle region in fever in sheep. Can J Physiol Pharmacol. 1987;65(6):1255–1260.PubMedGoogle Scholar
  26. 26.
    Boulant JA. Role of the preoptic-anterior hypothalamus in thermoregulation and fever. Clin Infect Dis. 2000;31(Suppl 5):S157–S161.PubMedGoogle Scholar
  27. 27.
    Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation. 1995;2(4):241–248.PubMedGoogle Scholar
  28. 28.
    Sehic E, Ungar AL, Blatteis CM. Interaction between norepinephrine and prostaglandin E2 in the preoptic area of guinea pigs. Am J Physiol. 1996;271(3(Pt. 2)):R528–R536.PubMedGoogle Scholar
  29. 29.
    Netea MG, Kullberg BJ, Van Der Meer JW. Do only circulating pyrogenic cytokines act as mediators in the febrile response? A hypothesis. Eur J Clin Invest. 1999;29(4):351–356.PubMedGoogle Scholar
  30. 30.
    Campisi J, Hansen MK, O’Connor KA, et al. Circulating cytokines and endotoxin are not necessary for the activation of the sickness or corticosterone response produced by peripheral E. coli challenge. J Appl Physiol. 2003;95(5):1873–1882.PubMedGoogle Scholar
  31. 31.
    Roth J, Martin D, Storr B, et al. Neutralization of pyrogen-induced tumour necrosis factor by its type 1 soluble receptor in guinea-pigs: effects on fever and interleukin-6 release. J Physiol. 1998;509(Pt. 1):267–275.PubMedGoogle Scholar
  32. 32.
    Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science. 1988;240(4850):321–324.PubMedGoogle Scholar
  33. 33.
    Skarnes RC, Brown SK, Hull SS, et al. Role of prostaglandin E in the biphasic fever response to endotoxin. J Exp Med. 1981;154(4):1212–1224.PubMedGoogle Scholar
  34. 34.
    Cavaillon JM, Fitting C, Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol. 1990;20(2):253–257.PubMedGoogle Scholar
  35. 35.
    Feldberg W, Myers RD. A new concept of temperature regulation by amines in the hypothalamus. Nature. 1963;200:1325.PubMedGoogle Scholar
  36. 36.
    Sehic E, Szekely M, Ungar AL, et al. Hypothalamic prostaglandin E2 during lipopolysaccharide-induced fever in guinea pigs. Brain Res Bull. 1996;39(6):391–399.PubMedGoogle Scholar
  37. 37.
    Maier SF, Goehler LE, Fleshner M, et al. The role of the vagus nerve in cytokine-to-brain communication. Ann NY Acad Sci. 1998;840:289–300.PubMedGoogle Scholar
  38. 38.
    Goldbach JM, Roth J, Zeisberger E. Fever suppression by subdiaphragmatic vagotomy in guinea pigs depends on the route of pyrogen administration. Am J Physiol. 1997;272(2(Pt. 2)):R675–R681.PubMedGoogle Scholar
  39. 39.
    Simons CT, Kulchitsky VA, Sugimoto N, et al. Signaling the brain in systemic inflammation: which vagal branch is involved in fever genesis? Am J Physiol. 1998;275(1(Pt. 2)):R63–R68.PubMedGoogle Scholar
  40. 40.
    Linthorst AC, Flachskamm C, Holsboer F, et al. Intraperitoneal administration of bacterial endotoxin enhances noradrenergic neurotransmission in the rat preoptic area: Relationship with body temperature and hypothalamic – pituitary – adrenocortical axis activity. Eur J Neurosci. 1995;7(12):2418–2430.PubMedGoogle Scholar
  41. 41.
    Shido O, Romanovsky AA, Ungar AL, et al. Role of intrapreoptic norepinephrine in endotoxin-induced fever in guinea pigs. Am J Physiol. 1993;265(6(Pt. 2)):R1369–R1375.PubMedGoogle Scholar
  42. 42.
    Leon LR, Kozak W, Kluger MJ. Role of IL-10 in inflammation: studies using cytokine knockout mice. Ann NY Acad Sci. 1998;856:69–75.PubMedGoogle Scholar
  43. 43.
    Pittman QJ, Chen X, Mouihate A, et al. Vasopressin-induced antipyresis. Sex- and experience-dependent febrile responses. Ann NY Acad Sci. 1998;856:53–61.PubMedGoogle Scholar
  44. 44.
    Carey F, Forder R, Edge MD, et al. Lipocortin 1 fragment modifies pyrogenic actions of cytokines in rats. Am J Physiol. 1990;259(2(Pt. 2)):R266–R269.PubMedGoogle Scholar
  45. 45.
    Steiner AA, Antunes-Rodrigues J, McCann SM, et al. Antipyretic role of the NO-cGMP pathway in the anteroventral preoptic region of the rat brain. Am J Physiol Regul Integr Comp Physiol. 2002;282(2):R584–R593.PubMedGoogle Scholar
  46. 46.
    Ensor JE, Wiener SM, McCrea KA, et al. Differential effects of hyperthermia on macrophage interleukin-6 and tumor necrosis factor-alpha expression. Am J Physiol. 1994;266(4(Pt. 1)):C967–C974.PubMedGoogle Scholar
  47. 47.
    Fouqueray B, Philippe C, Amrani A, et al. Heat shock prevents lipopolysaccharide-induced tumor necrosis factor-alpha synthesis by rat mononuclear phagocytes. Eur J Immunol. 1992;22(11):2983–2987.PubMedGoogle Scholar
  48. 48.
    Kappel M, Diamant M, Hansen MB, et al. Effects of in vitro hyperthermia on the proliferative response of blood mononuclear cell subsets, and detection of interleukins 1 and 6, tumour necrosis factor-alpha and interferon-gamma. Immunology. 1991;73(3):304–308.PubMedGoogle Scholar
  49. 49.
    Snyder YM, Guthrie L, Evans GF, et al. Transcriptional inhibition of endotoxin-induced monokine synthesis following heat shock in murine peritoneal macrophages. J Leukoc Biol. 1992;51(2):181–187.PubMedGoogle Scholar
  50. 50.
    Velasco S, Tarlow M, Olsen K, et al. Temperature-dependent modulation of lipopolysaccharide-induced interleukin-1 beta and tumor necrosis factor alpha expression in cultured human astroglial cells by dexamethasone and indomethacin. J Clin Invest. 1991;87(5):1674–1680.PubMedGoogle Scholar
  51. 51.
    Fulbrook P. Core body temperature measurement: a comparison of axilla, tympanic membrane and pulmonary artery blood temperature. Intensive Crit Care Nurs. 1997;13(5):266–272.PubMedGoogle Scholar
  52. 52.
    Jensen BN, Jensen FS, Madsen SN, et al. Accuracy of digital tympanic, oral, axillary, and rectal thermometers compared with standard rectal mercury thermometers. Eur J Surg. 2000;166(11):848–851.PubMedGoogle Scholar
  53. 53.
    Erickson RS, Kirklin SK. Comparison of ear-based, bladder, oral, and axillary methods for core temperature measurement. Crit Care Med. 1993;21(10):1528–1534.PubMedGoogle Scholar
  54. 54.
    Lefrant JY, Muller L, de La Coussaye JE, et al. Temperature measurement in intensive care patients: comparison of urinary bladder, esophageal, rectal, axillary, and inguinal methods versus pulmonary artery core method. Intensive Care Med. 2003;29(3):414–418.PubMedGoogle Scholar
  55. 55.
    Schmitz T, Bair N, Falk M, et al. A comparison of five methods of temperature measurement in febrile intensive care patients. Am J Crit Care. 1995;4(4):286–292.PubMedGoogle Scholar
  56. 56.
    Erickson RS. The continuing question of how best to measure body temperature. Crit Care Med. 1999;27(10):2307–2310.PubMedGoogle Scholar
  57. 57.
    Nierman DM. Core temperature measurement in the intensive care unit. Crit Care Med. 1991;19(6):818–823.PubMedGoogle Scholar
  58. 58.
    Moran JL, Peter JV, Solomon PJ, et al. Tympanic temperature measurements: are they reliable in the critically ill? A clinical study of measures of agreement. Crit Care Med. 2007;35(1):155–164.PubMedGoogle Scholar
  59. 59.
    Garrouste-Orgeas M, Timsit JF, Tafflet M, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis. 2006;42(8):1118–1126.PubMedGoogle Scholar
  60. 60.
    Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med. 1996;154(3(Pt. 1)):617–624.PubMedGoogle Scholar
  61. 61.
    Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32(3):858–873.PubMedGoogle Scholar
  62. 62.
    Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991;143(5(Pt. 1)):1121–1129.PubMedGoogle Scholar
  63. 63.
    Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med. 2004;30(5):844–852.PubMedGoogle Scholar
  64. 64.
    Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000;132(8):621–630.PubMedGoogle Scholar
  65. 65.
    The Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355:2619–2630.Google Scholar
  66. 66.
    American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.Google Scholar
  67. 67.
    Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis. 2001;7(2):342–347.PubMedGoogle Scholar
  68. 68.
    Leone M, Albanese J, Garnier F, et al. Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med. 2003;29(7):1077–1080.PubMedGoogle Scholar
  69. 69.
    Tambyah PA, Maki DG. The relationship between pyuria and infection in patients with indwelling urinary catheters: a prospective study of 761 patients. Arch Intern Med. 2000;160(5):673–677.PubMedGoogle Scholar
  70. 70.
    Platt R, Polk BF, Murdock B, et al. Risk factors for nosocomial urinary tract infection. Am J Epidemiol. 1986;124(6):977–985.PubMedGoogle Scholar
  71. 71.
    Rosser CJ, Bare RL, Meredith JW. Urinary tract infections in the critically ill patient with a urinary catheter. Am J Surg. 1999;177(4):287–290.PubMedGoogle Scholar
  72. 72.
    Stark RP, Maki DG. Bacteriuria in the catheterized patient: what quantitative level of bacteriuria is relevant? N Engl J Med. 1984;311(9):560–564.PubMedGoogle Scholar
  73. 73.
    Schwartz DS, Barone JE. Correlation of urinalysis and dipstick results with catheter-associated urinary tract infections in surgical ICU patients. Intensive Care Med. 2006;32(11):1797–1801.PubMedGoogle Scholar
  74. 74.
    Clec’h C, Schwebel C, Francais A, et al. Does catheter-associated urinary tract infection increase mortality in critically ill patients? Infect Control Hosp Epidemiol. 2007;28(12):1367–1373.PubMedGoogle Scholar
  75. 75.
    Bjork DT, Pelletier LL, Tight RR. Urinary tract infections with antibiotic resistant organisms in catheterized nursing home patients. Infect Control. 1984;5(4):173–176.PubMedGoogle Scholar
  76. 76.
    Leone M, Perrin AS, Granier I, et al. A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients. Intensive Care Med. 2007;33(4):726–729.PubMedGoogle Scholar
  77. 77.
    Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999;341(22):1645–1651.PubMedGoogle Scholar
  78. 78.
    McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320(4):204–210.PubMedGoogle Scholar
  79. 79.
    Wilcox MH. Cleaning up Clostridium difficile infection. Lancet. 1996;348(9030):767–768.PubMedGoogle Scholar
  80. 80.
    Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile. Lancet. 2000;356(9238):1324.PubMedGoogle Scholar
  81. 81.
    Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HIPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Am J Infect Control Suppl. 2002;30(8):S1–S46.Google Scholar
  82. 82.
    Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–2449.PubMedGoogle Scholar
  83. 83.
    Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273–280.PubMedGoogle Scholar
  84. 84.
    Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262.PubMedGoogle Scholar
  85. 85.
    Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med. 2001;161(4):525–533.PubMedGoogle Scholar
  86. 86.
    Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245(2):267–272.PubMedGoogle Scholar
  87. 87.
    Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(3):363–372.PubMedGoogle Scholar
  88. 88.
    Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145(10):758–764.PubMedGoogle Scholar
  89. 89.
    Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol. 2006;44(3):1145–1149.PubMedGoogle Scholar
  90. 90.
    Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997;92(5):739–750.PubMedGoogle Scholar
  91. 91.
    Johal SS, Hammond J, Solomon K, et al. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut. 2004;53(5):673–677.PubMedGoogle Scholar
  92. 92.
    Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8(2):149–154.PubMedGoogle Scholar
  93. 93.
    Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7–14.PubMedGoogle Scholar
  94. 94.
    Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274(8):639–644.PubMedGoogle Scholar
  95. 95.
    Bougnoux ME, Kac G, Aegerter P, et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008;34(2):292–299.PubMedGoogle Scholar
  96. 96.
    Bouza E, Sousa D, Muñoz P, et al. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis. 2004;39(8):1161–1169.PubMedGoogle Scholar
  97. 97.
    Golan Y, Wolf MP, Pauker SG, et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med. 2005;143(12):857–869.PubMedGoogle Scholar
  98. 98.
    Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29(2):239–244.PubMedGoogle Scholar
  99. 99.
    Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol. 2000;21(8):510–515.PubMedGoogle Scholar
  100. 100.
    Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37(5):634–643.PubMedGoogle Scholar
  101. 101.
    Blot SI, Vandewoude KH, Hoste EA, et al. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med. 2002;113(6):480–485.PubMedGoogle Scholar
  102. 102.
    DiNubile MJ, Lupinacci RJ, Strohmaier KM, et al. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care. 2007;22(3):237–244.PubMedGoogle Scholar
  103. 103.
    Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33(1):23–32.PubMedGoogle Scholar
  104. 104.
    Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3(11):685–702.PubMedGoogle Scholar
  105. 105.
    Horvath LL, Hospenthal DR, Murray CK, et al. Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles. J Clin Microbiol. 2003;41(10):4714–4717.PubMedGoogle Scholar
  106. 106.
    Schelonka RL, Moser SA. Time to positive culture results in neonatal Candida septicemia. J Pediatr. 2003;142(5):564–565.PubMedGoogle Scholar
  107. 107.
    Cohen R, Roth FJ, Delgado E, et al. Fungal flora of the normal human small and large intestine. N Engl J Med. 1969;280(12):638–641.PubMedGoogle Scholar
  108. 108.
    Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751–758.PubMedGoogle Scholar
  109. 109.
    Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730–737.PubMedGoogle Scholar
  110. 110.
    Charles PE, Dalle F, Aube H, et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 2005;31(3):393–400.PubMedGoogle Scholar
  111. 111.
    Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg. 2000;135(2):160–165.PubMedGoogle Scholar
  112. 112.
    Circiumaru B, Baldock G, Cohen J. A prospective study of fever in the intensive care unit. Intensive Care Med. 1999;25(7):668–673.PubMedGoogle Scholar
  113. 113.
    Fanning J, Neuhoff RA, Brewer JE, et al. Frequency and yield of postoperative fever evaluation. Infect Dis Obstet Gynecol. 1998;6(6):252–255.PubMedGoogle Scholar
  114. 114.
    Shaw JA, Chung R. Febrile response after knee and hip arthroplasty. Clin Orthop Relat Res. 1999;367:181–189.PubMedGoogle Scholar
  115. 115.
    Miyawaki T, Maeda S, Koyama Y, et al. Elevation of plasma interleukin-6 level is involved in postoperative fever following major oral and maxillofacial surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85(2):146–152.PubMedGoogle Scholar
  116. 116.
    Frank SM, Kluger MJ, Kunkel SL. Elevated thermostatic setpoint in postoperative patients. Anesthesiology. 2000;93(6):1426–1431.PubMedGoogle Scholar
  117. 117.
    Lofmark R, Nordlander R, Orinius E. The temperature course in acute myocardial infarction. Am Heart J. 1978;96(2):153–156.PubMedGoogle Scholar
  118. 118.
    Naito K, Anzai T, Yoshikawa T, et al. Increased body temperature after reperfused acute myocardial infarction is associated with adverse left ventricular remodeling. J Card Fail. 2007;13(1):25–33.PubMedGoogle Scholar
  119. 119.
    Ben-Dor I, Haim M, Rechavia E, et al. Body temperature: a marker of infarct size in the era of early reperfusion. Cardiology. 2005;103(4):169–173.PubMedGoogle Scholar
  120. 120.
    Fromm RE Jr. Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation. Crit Care Med. 2007;35(2):584–588.PubMedGoogle Scholar
  121. 121.
    Klein Gunnewiek JM, van de Leur JJ. Elevated troponin T concentrations in critically ill patients. Intensive Care Med. 2003;29(12):2317–2322.PubMedGoogle Scholar
  122. 122.
    Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med. 1999;27(9):1775–1780.PubMedGoogle Scholar
  123. 123.
    Lim W, Qushmaq I, Cook DJ, et al. Elevated troponin and myocardial infarction in the intensive care unit: a prospective study. Crit Care. 2005;9(6):R636–R644.PubMedGoogle Scholar
  124. 124.
    Calvo-Romero JM, Lima-Rodriguez EM, Perez-Miranda M, et al. Low-grade and high-grade fever at presentation of acute pulmonary embolism. Blood Coagul Fibrinolysis. 2004;15(4):331–333.PubMedGoogle Scholar
  125. 125.
    Stein PD, Afzal A, Henry JW, et al. Fever in acute pulmonary embolism. Chest. 2000;117(1):39–42.PubMedGoogle Scholar
  126. 126.
    Kazmers A, Groehn H, Meeker C. Do patients with acute deep vein thrombosis have fever? Am J Surg. 2000;66(6):598–601.Google Scholar
  127. 127.
    Jaramillo EJ, Trevino JM, Berghoff KR, et al. Bedside diagnostic laparoscopy in the intensive care unit: a 13-year experience. JSLS. 2006;10(2):155–159.PubMedGoogle Scholar
  128. 128.
    Laurila J, Syrjala H, Laurila PA, et al. Acute acalculous cholecystitis in critically ill patients. Acta Anaesthesiol Scand. 2004;48(8):986–991.PubMedGoogle Scholar
  129. 129.
    Pelinka LE, Schmidhammer R, Hamid L, et al. Acute acalculous cholecystitis after trauma: a prospective study. J Trauma. 2003;55(2):323–329.PubMedGoogle Scholar
  130. 130.
    Ko CW, Lee SP. Gastrointestinal disorders of the critically ill: biliary sludge and cholecystitis. Best Pract Res Clin Gastroenterol. 2003;17(3):383–396.PubMedGoogle Scholar
  131. 131.
    Rady MY, Kodavatiganti R, Ryan T. Perioperative predictors of acute cholecystitis after cardiovascular surgery. Chest. 1998;114(1):76–84.PubMedGoogle Scholar
  132. 132.
    Trowbridge RL, Rutkowski NK, Shojania KG. Does this patient have acute cholecystitis? JAMA. 2003;289(1):80–86.PubMedGoogle Scholar
  133. 133.
    Geraghty PJ, Sanchez LA, Rubin BG, et al. Overt ischemic colitis after endovascular repair of aortoiliac aneurysms. J Vasc Surg. 2004;40(3):413–418.PubMedGoogle Scholar
  134. 134.
    Maldonado TS, Rockman CB, Riles E, et al. Ischemic compli­cations after endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2004;40(4):703–709. discussion 709–710.PubMedGoogle Scholar
  135. 135.
    Saito A, Shirai Y, Ohzeki H, et al. Acute acalculous cholecystitis after cardiovascular surgery. Surg Today. 1997;27(10):907–909.PubMedGoogle Scholar
  136. 136.
    Orlando R III, Gleason E, Drezner AD. Acute acalculous cholecystitis in the critically ill patient. Am J Surg. 1983;145(4):472–476.PubMedGoogle Scholar
  137. 137.
    Ceppa EP, Fuh KC, Bulkley GB. Mesenteric hemodynamic response to circulatory shock. Curr Opin Crit Care. 2003;9(2):127–132.PubMedGoogle Scholar
  138. 138.
    Acosta S, Ogren M, Sternby NH, et al. Fatal nonocclusive mesenteric ischaemia: population-based incidence and risk factors. J Intern Med. 2006;259(3):305–313.PubMedGoogle Scholar
  139. 139.
    Aldrete JS, Han SY, Laws HL, et al. Intestinal infarction complicating low cardiac output states. Surg Gynecol Obstet. 1977;144(3):371–375.PubMedGoogle Scholar
  140. 140.
    Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care: transfusion requirements in critical care investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409–417.PubMedGoogle Scholar
  141. 141.
    Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29(2):227–234.PubMedGoogle Scholar
  142. 142.
    Habler O. Cardiac high-risk patients: from “permissive” to “deliberate” anemia. Crit Care Med. 2005;33(10):2434–2435.PubMedGoogle Scholar
  143. 143.
    Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU: is there a reason? Chest. 1995;108(3):767–771.PubMedGoogle Scholar
  144. 144.
    Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1499–1507.PubMedGoogle Scholar
  145. 145.
    Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: anemia and blood transfusion in the critically ill – current clinical practice in the United States. Crit Care Med. 2004;32(1):39–52.PubMedGoogle Scholar
  146. 146.
    Ezidiegwu CN, Lauenstein KJ, Rosales LG, et al. Febrile nonhemolytic transfusion reactions: management by premedication and cost implications in adult patients. Arch Pathol Lab Med. 2004;128(9):991–995.PubMedGoogle Scholar
  147. 147.
    Zhao SM, Cheng XL, Hu J, et al. Clinical assessment of preventing febrile nonhemolytic transfusion reaction by leukocyte-depleted blood transfusion. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002;10(6):568–570.PubMedGoogle Scholar
  148. 148.
    Oberman HA. Controversies in transfusion medicine: should a febrile transfusion response occasion the return of the blood component to the blood bank? Con Transfusion. 1994;34(4):353–355.Google Scholar
  149. 149.
    Widmann FK. Controversies in transfusion medicine: should a febrile transfusion response occasion the return of the blood component to the blood bank? Pro Transfusion. 1994;34(4):356–358.Google Scholar
  150. 150.
    Andreu G, Morel P, Forestier F, et al. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42(10):1356–1364.PubMedGoogle Scholar
  151. 151.
    Klein HG, Dodd RY, Ness PM, et al. Current status of microbial contamination of blood components: summary of a conference. Transfusion. 1997;37(1):95–101.PubMedGoogle Scholar
  152. 152.
    Goldman M, Blajchman MA. Blood product-associated bacterial sepsis. Transfus Med Rev. 1991;5(1):73–83.PubMedGoogle Scholar
  153. 153.
    Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine – blood transfusion – first of two parts. N Engl J Med. 1999;340:438–447.PubMedGoogle Scholar
  154. 154.
    Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion. 1992;32(7):601–606.PubMedGoogle Scholar
  155. 155.
    Ness PM, Shirey RS, Thoman SK, et al. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion. 1990;30(8):688–693.PubMedGoogle Scholar
  156. 156.
    Shulman IA, Odono V. The risk of overt acute hemolytic transfusion reaction following the use of an immediate-spin crossmatch. Transfusion. 1994;34(1):87–88.PubMedGoogle Scholar
  157. 157.
    Shepherd GM. Hypersensitivity reactions to drugs: evaluation and management. Mt Sinai J Med. 2003;70(2):113–125.PubMedGoogle Scholar
  158. 158.
    Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123–129.PubMedGoogle Scholar
  159. 159.
    Kay AB. Allergy and allergic diseases: first of two parts. N Engl J Med. 2001;344(1):30–37.PubMedGoogle Scholar
  160. 160.
    Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250–257.PubMedGoogle Scholar
  161. 161.
    Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007;62(1):47–52.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Alexis Tabah
    • 1
  • François Philippart
    • 2
  • Jean Carlet
    • 3
  1. 1.Medical Intensive Care MedicineMichallon Teaching HospitalLa TroncheFrance
  2. 2.Department of Intensive Care MedicineGroupe Hospitalier Paris Saint JosephParisFrance
  3. 3.Department of RéanimationGroupe Hospitalier Paris — St, JosephParisFrance

Personalised recommendations